GammaCan to work on VitiGam

Advanced stage melanoma represents a large unmet medical need as there currently are no safe and effective therapies available to patients, the companies said.

By JERUSALEM POST STAFF
August 23, 2006 08:34

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

GammaCan International and Life Therapeutics on Tuesday signed a term sheet to collaborate to jointly develop VitiGam, an innovative, anti-cancer product designed to target metastatic malignant melanoma patients with Stage III and IV disease. Advanced stage melanoma represents a large unmet medical need as there currently are no safe and effective therapies available to patients, the companies said. The partners will share the costs and expenses relating to the development, supply, collection, manufacture, storage and commercialization of VitiGam, as well as their respective portion in any proceeds resulting of the collaboration. Life Therapeutics will also supply plasma to GammaCan for the project.

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS